whether neoadjuvant chemotherapy was administered with trastuzumab alone or with an additional HER2-targeted agent, pathological nodal status at surgery, age cohorts, and race. However ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Herceptin SC? Herceptin SC contains the active ...

HER2-overexpressing breast cancer Trastuzumab, in combination with an anthracycline- and taxane-containing chemotherapy regimen, has become the universally-accepted standard of care for high-risk ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.

In contrast, Herceptin/Perjeta administration needs ... Phesgo has been recommended by the CHMP for use in combination with chemotherapy in early HER2-positive breast cancer – pre- and post ...